Multiple myeloma and other plasma cell neoplasms. ([2018])

• Record Type: Book
• Further Information: Note: Meletios A. Dimopoulos, Thierry Facon, Evangelos Terpos, editors.
• Editors: Dimopoulos, Meletios; Facon, Thierry, 1959-; Terpos, Evangelos
• Contents: Intro; Contents; 1: Epidemiology and Pathophysiology of Multiple Myeloma; 1.1 Introduction; 1.2 Epidemiology; 1.3 Genetic Landscape of Multiple Myeloma; 1.4 Chromosomal Abnormalities; 1.4.1 IgH Translocations; 1.4.2 Hyperdiploidy; 1.4.3 Secondary Translocations in Myeloma; 1.4.4 Copy Number Variations; 1.5 Somatic Mutations; 1.5.1 Clonal Evolution; 1.5.2 Prognostic Impact; 1.5.3 Relapse; 1.6 Gene Expression; 1.7 Bone Marrow Microenvironment; 1.8 Future Perspective; References; 2: Diagnosis and Staging of Multiple Myeloma and Related Disorders; 2.1 Disease Definition 2.1.1 New Diagnostic Criteria for MM2.1.1.1 Clonal Bone Marrow Plasma Cells; 2.1.1.2 Elevated Serum Involved/Uninvolved FLC Ratio â#x89;{u00A5}100; 2.1.1.3 More than One Focal Lesion on MRI; 2.1.1.4 Imaging Requirements; 2.1.1.5 Other Miscellaneous Changes; 2.2 New Diagnostic Criteria for SMM; 2.3 Molecular Classification of Myeloma; 2.4 Staging and Risk Stratification; 2.4.1 Revised International Staging System for MM; 2.4.2 Risk Stratification of SMM; 2.5 Response Assessment and Monitoring; References; 3: Treatment of Transplant Eligible Patients with Multiple Myeloma 3.1 Part 1: High-Dose Therapy3.1.1 Introduction; 3.1.1.1 HDT and ASCT: The Principle; 3.1.2 Induction Treatment Prior to HDT; 3.1.2.1 Conditioning Regimens Prior to ASCT; 3.1.2.2 Single Versus Double ASCT; 3.2 Part 2: Consolidation and Maintenance; 3.2.1 Consolidation; 3.2.2 Transplantation as Consolidation Therapy; 3.2.3 Novel Agents as Consolidation Therapy After ASCT; 3.2.3.1 Conventional Chemotherapy with or Without Thalidomide; 3.2.3.2 Bortezomib; 3.2.3.3 Bortezomib in Combination with IMiDs; 3.2.3.4 Lenalidomide 3.2.3.5 Ongoing Studies Exploring the Role of Novel-Agent-Based Consolidation Therapy3.2.4 Toxicities Related to Consolidation Therapy; 3.2.5 Conclusion and Open Issues; 3.3 Maintenance; 3.3.1 Introduction; 3.3.2 Maintenance Treatment in the Pre-Novel Agent Era: Chemotherapy and Steroids; 3.3.3 Maintenance Treatment in the Era of Novel Agents; 3.3.3.1 Thalidomide; 3.3.3.2 Bortezomib; 3.3.3.3 Lenalidomide; 3.3.3.4 Monoclonal Antibodies; 3.3.4 Toxicity and Secondary Primary Malignancies; 3.3.5 Which Group of Patients Benefit the Most from Maintenance Treatment? 3.3.6 Conclusions3.4 Part 3: Allogeneic Stem Cell Transplantation; 3.4.1 Front-Line Treatment; 3.4.2 Treatment for Relapsed Disease; 3.4.3 How to Increase the Graft{u00AD}Versus Myeloma Effect After Allogeneic SCT; 3.4.3.1 Donor Lymphocyte Infusions (DLI); 3.4.3.2 Lenalidomide Post-AlloSCT; References; 4: Treatment of Elderly Patients with Multiple Myeloma; 4.1 Introduction; 4.2 What is Special about Myeloma in the Elderly; 4.2.1 Myeloma Cytogenetics and Biology; 4.2.2 Clinical Features; 4.3 Induction Treatment; 4.3.1 When to Treat?; 4.3.2 What to Aim for?
• Publisher Details: Cham, Switzerland : Springer
• Publication Date: 2018
• Copyright Date: 2018
• Extent: 1 online resource, color illustrations
• Subjects: 616.99/418; Medicine; Multiple myeloma; HEALTH & FITNESS -- Diseases -- General; MEDICAL -- Clinical Medicine; MEDICAL -- Diseases; MEDICAL -- Evidence-Based Medicine; MEDICAL -- Internal Medicine; Multiple myeloma; Multiple Myeloma -- diagnosis; Multiple Myeloma -- therapy; Neoplasms, Plasma Cell; Medical -- Oncology; Medical -- Immunology; Oncology; Immunology; Hematology; Oncology ; Immunology; Medical -- Hematology; Haematology; Electronic books
• Languages: English
• ISBNs: 9783319255866
• Related ISBNs: 331925586X; 9783319255842; 3319255843
• Notes: Note: Includes bibliographical references.
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.